Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-6 receptor subunit beta (gp130), encoded by the IL6ST gene, is a ubiquitously expressed transmembrane glycoprotein that serves as the shared signal-transducing subunit for the interleukin-6 (IL-6) family of cytokines, including IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), and ciliary neurotrophic factor (CNTF). Upon cytokine binding to their specific alpha-receptor subunits, gp130 undergoes homodimerization or heterodimerization, which activates associated Janus kinases (JAKs) and subsequently phosphorylates downstream signal transducer and activator of transcription (STAT) proteins, particularly STAT3, as well as the MAPK and PI3K/Akt pathways. This signaling cascade plays a critical role in regulating immune responses, hematopoiesis, cell proliferation, survival, and tissue regeneration. Aberrant activation of gp130 signaling is strongly implicated in chronic inflammatory diseases, autoimmune disorders (such as rheumatoid arthritis and inflammatory bowel disease), and various cancers, where it drives tumor growth, metastasis, and chemoresistance. Consequently, gp130 has emerged as a highly attractive therapeutic target. Therapeutic strategies include the selective blockade of IL-6 trans-signaling using the soluble gp130-Fc fusion protein olamkicept, as well as small-molecule inhibitors like bazedoxifene and SC144 that directly disrupt gp130 dimerization and downstream STAT3 activation.
Inhibition of gp130 homodimerization and heterodimerization, selective blockade of IL-6 trans-signaling, and suppression of downstream JAK/STAT3 signaling.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-6 receptor subunit beta (gp130) (IL6ST).